diprenorphine
Small moleculeexperimental
Diprenorphine, also known as diprenorfin, is a non-selective, high-affinity, weak partial agonist of the μ- (MOR), κ- (KOR), and δ-opioid receptor (DOR) which is used in veterinary medicine as an opioid antagonist. It is used to reverse the effects of super-potent opioid analgesics such as etorphine and carfentanil that are used for tranquilizing large animals. The drug is not approved for use in humans. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT02524301)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5- Mol. weight
- 425.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDiprenorphine ↗
- ChEMBLCHEMBL281786 ↗
Also known as
- diprenorfin
- diprenorfin
- diprenorphine
- diprenorphine
- diprenorphine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02112695 | N/A | Sep 15, 2014 | Government of France, University of Lyon |
| NCT02524301 | N/A | Sep 1, 2009 | Government of France, University of Lyon |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of France | Government | 2 | 0 | 1 | 2009 |
| University of Lyon | Academic/Hospital | 2 | 2 | 1 | 2009 |
2 organizations
Page 1 / 1